Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

31 March 2024

  • curprev 13:0613:06, 31 March 2024‎ Lazy talk contribs‎ 3,218 bytes +3,218‎ Created page with "{{TreatmentInfo |drug_name=Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine |FDA_approval=In clinical trials; not yet FDA-approved |used_for=Recurrent heavily pretreated glioblastoma multiforme (GBM) and newly diagnosed GBM |clinical_trial_phase=Phase II |common_side_effects=Not explicitly detailed; similar immunotherapy treatments often include flu-like symptoms, injection site reactions, fatigue |OS_without=Historical controls suggest a median survival t..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Agenus_Prophage_(Heat-Shock_Protein_Peptide_Complex-96)_Vaccine"